The Emerging Role of Left Bundle Branch Area Pacing for Cardiac Resynchronisation Therapy

Juan Carlos Diaz1, Mauricio Duque1, Julian Aristizabal2

  • 1Cardiac Arrhythmia and Electrophysiology Service, Division of Cardiology, Clinica Las Vegas, Universidad CES Medical School Medellin, Colombia.

Insights

Left bundle branch area pacing (LBBAP) offers a promising alternative to traditional cardiac resynchronisation therapy (CRT) for heart failure patients. LBBAP may improve outcomes by stimulating the heart

Area of Science:

  • Cardiology
  • Electrophysiology
  • Heart Failure Management

Background:

  • Cardiac resynchronisation therapy (CRT) improves outcomes in heart failure patients with left bundle branch block (LBBB).
  • Traditional CRT via coronary sinus lead has limitations, including procedural failure and suboptimal patient response.
  • A significant portion of patients do not benefit from conventional CRT.

Purpose of the Study:

  • To review the evidence supporting left bundle branch area pacing (LBBAP) as an alternative to traditional CRT.
  • To explore the potential benefits of LBBAP in heart failure management.

Main Methods:

  • Review of existing scientific literature and clinical evidence on LBBAP in heart failure patients.
  • Comparison of LBBAP physiological stimulation with conventional CRT approaches.

Main Results:

  • LBBAP stimulates the cardiac conduction system more physiologically than traditional CRT.
  • This approach may lead to more homogeneous left ventricular contraction and relaxation.
  • LBBAP has the potential to overcome limitations associated with conventional CRT.

Conclusions:

  • Left bundle branch area pacing (LBBAP) presents a viable and potentially superior alternative to traditional CRT.
  • LBBAP may offer improved outcomes for heart failure patients with LBBB.
  • Further research and clinical adoption of LBBAP are warranted.

Related Concept Videos

Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Disturbances in Heart Rhythm01:29

Disturbances in Heart Rhythm

Arrhythmia or dysrhythmia refers to an abnormal heart rhythm caused by a defect in the heart's conduction system. It can cause the heart to beat irregularly, too quickly, or too slowly, leading to symptoms like chest pain, shortness of breath, and fainting. Factors such as stress, caffeine, alcohol, nicotine, cocaine, certain drugs, congenital defects, diseases, and electrolyte abnormalities can trigger arrhythmias.
Arrhythmias are categorized by their speed, rhythm, and origin. A slow heart...
Imbalances in Cardiac Output01:26

Imbalances in Cardiac Output

The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send blood...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...